JNJ-39220675 | CAS#959740-39-7 | Histamine H3 receptor antagonist

MedKoo Cat#: 525326 | Name: JNJ-39220675

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JNJ-39220675 is a novel selective histamine H3 receptor antagonist. JNJ-39220675 reduces the abuse-related effects of alcohol in rats.

Chemical Structure

JNJ-39220675

CAS#959740-39-7

Theoretical Analysis

MedKoo Cat#: 525326

Name: JNJ-39220675

CAS#: 959740-39-7

Chemical Formula: C21H24FN3O2

Exact Mass: 369.1853

Molecular Weight: 369.43

Elemental Analysis: C, 68.27; H, 6.55; F, 5.14; N, 11.37; O, 8.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

JNJ-39220675; JNJ 39220675; JNJ39220675.

IUPAC/Chemical Name

(4-cyclobutyl-1,4-diazepan-1-yl)(6-(4-fluorophenoxy)pyridin-3-yl)methanone

InChi Key

IQOWHZHNGJXGHG-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H24FN3O2/c22-17-6-8-19(9-7-17)27-20-10-5-16(15-23-20)21(26)25-12-2-11-24(13-14-25)18-3-1-4-18/h5-10,15,18H,1-4,11-14H2

SMILES Code

O=C(N1CCCN(C2CCC2)CC1)c3cnc(Oc4ccc(F)cc4)cc3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 369.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Nuutinen S, Panula P, Salminen O. Different Hypothalamic Nicotinic α7 Receptor Expression and Response to Low Nicotine Dose in Alcohol-Preferring and Alcohol-Avoiding Rats. Alcohol Clin Exp Res. 2016 Feb;40(2):329-34. doi: 10.1111/acer.12960. PubMed PMID: 26842251. 2: Vanhanen J, Kinnunen M, Nuutinen S, Panula P. Histamine H3 receptor antagonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs. Psychopharmacology (Berl). 2015 Mar;232(6):1143-53. doi: 10.1007/s00213-014-3751-7. Epub 2014 Oct 12. PubMed PMID: 25308376. 3: Barchuk WT, Salapatek AM, Ge T, D'Angelo P, Liu X. A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion. J Allergy Clin Immunol. 2013 Oct;132(4):838-46.e1-6. doi: 10.1016/j.jaci.2013.05.001. Epub 2013 Jun 20. PubMed PMID: 23791513. 4: Vanhanen J, Nuutinen S, Lintunen M, Mäki T, Rämö J, Karlstedt K, Panula P. Histamine is required for H₃ receptor-mediated alcohol reward inhibition, but not for alcohol consumption or stimulation. Br J Pharmacol. 2013 Sep;170(1):177-87. doi: 10.1111/bph.12170. PubMed PMID: 23489295; PubMed Central PMCID: PMC3764859. 5: Logan J, Carruthers NI, Letavic MA, Sands S, Jiang X, Shea C, Muench L, Xu Y, Carter P, King P, Fowler JS. Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [¹¹C]GSK189254 in anesthetized baboon. Psychopharmacology (Berl). 2012 Oct;223(4):447-55. Epub 2012 May 22. PubMed PMID: 22614669; PubMed Central PMCID: PMC3456925. 6: Rezvani AH, Lawrence AJ, Arolfo MP, Levin ED, Overstreet DH. Novel medication targets for the treatment of alcoholism: preclinical studies. Recent Pat CNS Drug Discov. 2012 Aug;7(2):151-62. Review. PubMed PMID: 22574676. 7: Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, Boggs J, Welty N, Shoblock JR, Motley ST, Letavic MA, Carruthers NI, Dugovic C, Lovenberg TW, Bonaventure P. JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41. doi: 10.1007/s00213-010-2092-4. Epub 2010 Nov 18. PubMed PMID: 21086115. 8: Letavic MA, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, Everson A, Feinstein MA, Fraser IC, Hoey K, Jiang X, Keith JM, Koudriakova T, Leung P, Lord B, Lovenberg TW, Ly KS, Morton KL, Motley ST, Nepomuceno D, Rizzolio M, Rynberg R, Sepassi K, Shelton J. Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical development. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4210-4. doi: 10.1016/j.bmcl.2010.05.041. Epub 2010 May 16. PubMed PMID: 20561786.